Combination of B7-H4-TOP1i ADC, PD-1/TIGIT bispecific antibody, and PARP inhibition orchestrates angiogenesis suppression and interferon-program activation in a syngeneic mouse model

puxitatug samrotecan (AZD8205) - AstraZeneca

rilvegostomig (AZD2936) - AstraZeneca

saruparib (AZD5305) - AstraZeneca

https://www.abstractsonline.com/pp8/#!/21436/presentation/3455

Octavio Morante-Palacios1; Jon Chesebrough2; Yoshimi Johnson3; Raymond Rothstein3; Varsha Shankarappa4; Joseph Boland5; Elizabeth Galery5; Anna Dominika Staniszewska6; Mark R. Albertella6; Alex Cazes2; Paul Chariou3; Bilal Omar3

Mar 18, 2026